ChromaDex Corporation (CDXC)
NASDAQ: CDXC · IEX Real-Time Price · USD
3.070
-0.120 (-3.76%)
Jul 26, 2024, 4:00 PM EDT - Market closed
ChromaDex Revenue
ChromaDex had revenue of $22.15M in the quarter ending March 31, 2024, a decrease of -1.79%. This brings the company's revenue in the last twelve months to $83.17M, up 7.52% year-over-year. In the year 2023, ChromaDex had annual revenue of $83.57M with 15.99% growth.
Revenue (ttm)
$83.17M
Revenue Growth
+7.52%
P/S Ratio
2.79
Revenue / Employee
$784,594
Employees
106
Market Cap
231.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
Dec 31, 2019 | 46.29M | 14.73M | 46.69% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Jan 2, 2016 | Pro | Pro | Pro |
Jan 3, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chegg | 703.04M |
Whole Earth Brands | 548.00M |
Nature's Sunshine Products | 447.68M |
The Beauty Health Company | 393.12M |
Vasta Platform | 306.99M |
Forafric Global | 305.48M |
Lifeway Foods | 166.85M |
Mama's Creations | 110.00M |
CDXC News
- 2 days ago - ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 - Business Wire
- 3 days ago - ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) - Business Wire
- 4 days ago - ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel - Business Wire
- 10 days ago - ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August - Business Wire
- 25 days ago - ChromaDex to Join Russell 2000® Index - Business Wire
- 4 weeks ago - Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) - Business Wire
- 6 weeks ago - ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) - Business Wire
- 7 weeks ago - ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) - Business Wire